Share on Facebook
Share on Twitter
Share on LinkedIn
Share by Email
Print
Adbry Generic Name & Formulations
Legal Class
Rx
General Description
Tralokinumab-ldrm 150mg/mL; soln for SC inj; preservative-free.
Pharmacological Class
Interleukin-13 (IL-13) antagonist.
How Supplied
Single-dose prefilled syringe (w. needle guard)—2, 4
Manufacturer
Generic Availability
NO
Adbry Indications
Indications
Moderate to severe atopic dermatitis in adults whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. May be used with or without topical corticosteroids.
Adbry Dosage and Administration
Adult
Give by SC inj into the thigh or abdomen (except for 2 inches around the navel); upper arm may be used if caregiver administers inj. Rotate inj sites. Initially 600mg (four 150mg inj), followed by 300mg (two 150mg inj) every other week. After 16 weeks, may consider 300mg every 4 weeks for patients weighing <100kg who achieve clear or almost clear skin. Concomitant topical calcineurin inhibitors: reserve for problem areas only (eg, face, neck, intertriginous, genital areas).
Children
Not established.
Adbry Contraindications
Not Applicable
Adbry Boxed Warnings
Not Applicable
Adbry Warnings/Precautions
Warnings/Precautions
Discontinue immediately if serious hypersensitivity reactions occur. New onset or worsening eye symptoms. Helminth infections: treat pre-existing infections prior to initiation; discontinue Adbry if become infected during therapy until infection resolves. Complete all vaccinations according to current guidelines prior to initiation. Pregnancy. Nursing mothers.
Adbry Pharmacokinetics
See Literature
Adbry Interactions
Interactions
Avoid concomitant live vaccines.
Adbry Adverse Reactions
Adverse Reactions
Upper respiratory tract infections, conjunctivitis, inj site reactions, eosinophilia; anaphylaxis, angioedema, keratitis.
Adbry Clinical Trials
See Literature
Adbry Note
Not Applicable
Adbry Patient Counseling
See Literature
